Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

On February 8, 2021

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

GE Healthcare update on iodinated contrast media

Tyson Foods Announces Quarterly Dividend

HII’s Newport News Shipbuilding Hiring Thousands